(DLB) Dolby Laboratories - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US25659T1079
Stock: Audio Codecs, Video Codecs, Cinema Systems, Immersive Media
Total Rating 33
Risk 87
Buy Signal -0.66
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.83% |
| Yield on Cost 5y | 1.58% |
| Yield CAGR 5y | 10.36% |
| Payout Consistency | 87.0% |
| Payout Ratio | 27.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.9% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.15 |
| Alpha | -38.70 |
| Character TTM | |
|---|---|
| Beta | 0.805 |
| Beta Downside | 0.801 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.66% |
| CAGR/Max DD | -0.24 |
Description: DLB Dolby Laboratories January 07, 2026
Dolby Laboratories (NYSE:DLB) designs and manufactures audio, imaging, and accessibility hardware and software for TV, broadcast, and live-entertainment markets worldwide, licensing its core codecs (AAC, HE-AAC, Dolby Atmos, Dolby Vision, DD+, AC-4, HEVC) to device makers, content creators, and service providers.
The firm’s product portfolio spans premium cinema solutions (Dolby Cinemas), a cloud-based developer platform (Dolby.io) for real-time immersive experiences, and a suite of digital cinema servers, processors, amplifiers, and loudspeakers that support theatrical, broadcast, and home-entertainment distribution.
Recent KPI highlights: FY 2024 revenue grew ~9% YoY to $1.78 billion, with the SaaS segment (Dolby.io) posting a 35% compound annual growth rate over the past three years, and operating margin expanding to 21% as licensing revenue benefits from the global shift toward streaming and immersive content. Key sector drivers include rising consumer demand for high-dynamic-range video and object-based audio in OTT platforms, and the continued rollout of 5G, which accelerates adoption of low-latency, cloud-native media workflows.
For a deeper quantitative look at Dolby’s valuation dynamics, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 276.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -0.59 > 1.0 |
| NWC/Revenue: 72.04% < 20% (prev 64.17%; Δ 7.87% < -1%) |
| CFO/TA 0.13 > 3% & CFO 420.2m > Net Income 276.7m |
| Net Debt (-603.2m) to EBITDA (379.1m): -1.59 < 3 |
| Current Ratio: 3.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.5m) vs 12m ago -0.65% < -2% |
| Gross Margin: 87.86% > 18% (prev 0.89%; Δ 8697 % > 0.5%) |
| Asset Turnover: 42.16% > 50% (prev 41.64%; Δ 0.53% > 0%) |
| Interest Coverage Ratio: 67.72 > 6 (EBITDA TTM 379.1m / Interest Expense TTM 4.12m) |
Altman Z'' 9.85
| A: 0.30 (Total Current Assets 1.41b - Total Current Liabilities 443.5m) / Total Assets 3.19b |
| B: 0.82 (Retained Earnings 2.60b / Total Assets 3.19b) |
| C: 0.09 (EBIT TTM 278.9m / Avg Total Assets 3.18b) |
| D: 4.40 (Book Value of Equity 2.59b / Total Liabilities 589.3m) |
| Altman-Z'' Score: 9.85 = AAA |
Beneish M -3.38
| DSRI: 0.65 (Receivables 373.1m/560.2m, Revenue 1.34b/1.32b) |
| GMI: 1.01 (GM 87.86% / 88.65%) |
| AQI: 0.93 (AQ_t 0.40 / AQ_t-1 0.43) |
| SGI: 1.02 (Revenue 1.34b / 1.32b) |
| TATA: -0.04 (NI 276.7m - CFO 420.2m) / TA 3.19b) |
| Beneish M-Score: -3.38 (Cap -4..+1) = AA |
What is the price of DLB shares?
As of February 03, 2026, the stock is trading at USD 64.50 with a total of 1,011,859 shares traded.
Over the past week, the price has changed by +3.83%, over one month by +1.53%, over three months by -2.29% and over the past year by -21.94%.
Over the past week, the price has changed by +3.83%, over one month by +1.53%, over three months by -2.29% and over the past year by -21.94%.
Is DLB a buy, sell or hold?
Dolby Laboratories has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy DLB.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.3 | 38.4% |
| Analysts Target Price | 89.3 | 38.4% |
| ValueRay Target Price | 61.7 | -4.4% |
DLB Fundamental Data Overview February 01, 2026
P/E Trailing = 24.5
P/E Forward = 13.947
P/S = 4.5441
P/B = 2.3645
P/EG = 2.0755
Revenue TTM = 1.34b USD
EBIT TTM = 278.9m USD
EBITDA TTM = 379.1m USD
Long Term Debt = 40.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 40.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -603.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.53b USD (6.13b + Debt 40.6m - CCE 644.6m)
Interest Coverage Ratio = 67.72 (Ebit TTM 278.9m / Interest Expense TTM 4.12m)
EV/FCF = 14.53x (Enterprise Value 5.53b / FCF TTM 380.4m)
FCF Yield = 6.88% (FCF TTM 380.4m / Enterprise Value 5.53b)
FCF Margin = 28.41% (FCF TTM 380.4m / Revenue TTM 1.34b)
Net Margin = 20.67% (Net Income TTM 276.7m / Revenue TTM 1.34b)
Gross Margin = 87.86% ((Revenue TTM 1.34b - Cost of Revenue TTM 162.6m) / Revenue TTM)
Gross Margin QoQ = 87.54% (prev 87.13%)
Tobins Q-Ratio = 1.73 (Enterprise Value 5.53b / Total Assets 3.19b)
Interest Expense / Debt = 10.13% (Interest Expense 4.12m / Debt 40.6m)
Taxrate = 25.03% (17.9m / 71.6m)
NOPAT = 209.1m (EBIT 278.9m * (1 - 25.03%))
Current Ratio = 3.17 (Total Current Assets 1.41b / Total Current Liabilities 443.5m)
Debt / Equity = 0.02 (Debt 40.6m / totalStockholderEquity, last quarter 2.59b)
Debt / EBITDA = -1.59 (Net Debt -603.2m / EBITDA 379.1m)
Debt / FCF = -1.59 (Net Debt -603.2m / FCF TTM 380.4m)
Total Stockholder Equity = 2.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.71% (Net Income 276.7m / Total Assets 3.19b)
RoE = 10.65% (Net Income TTM 276.7m / Total Stockholder Equity 2.60b)
RoCE = 10.57% (EBIT 278.9m / Capital Employed (Equity 2.60b + L.T.Debt 40.6m))
RoIC = 8.05% (NOPAT 209.1m / Invested Capital 2.60b)
WACC = 8.87% (E(6.13b)/V(6.17b) * Re(8.88%) + D(40.6m)/V(6.17b) * Rd(10.13%) * (1-Tc(0.25)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.47%
[DCF Debug] Terminal Value 75.80% ; FCFF base≈386.2m ; Y1≈407.0m ; Y5≈478.7m
Fair Price DCF = 127.4 (EV 7.11b - Net Debt -603.2m = Equity 7.72b / Shares 60.6m; r=8.87% [WACC]; 5y FCF grow 5.89% → 2.90% )
EPS Correlation: 19.21 | EPS CAGR: 3.85% | SUE: -0.61 | # QB: 0
Revenue Correlation: 24.78 | Revenue CAGR: 0.97% | SUE: 0.85 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.34 | Chg30d=-0.019 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-09-30): EPS=4.36 | Chg30d=+0.095 | Revisions Net=+1 | Growth EPS=+2.7% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.63 | Chg30d=+0.033 | Revisions Net=+1 | Growth EPS=+6.4% | Growth Revenue=+4.1%
P/E Forward = 13.947
P/S = 4.5441
P/B = 2.3645
P/EG = 2.0755
Revenue TTM = 1.34b USD
EBIT TTM = 278.9m USD
EBITDA TTM = 379.1m USD
Long Term Debt = 40.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 40.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -603.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.53b USD (6.13b + Debt 40.6m - CCE 644.6m)
Interest Coverage Ratio = 67.72 (Ebit TTM 278.9m / Interest Expense TTM 4.12m)
EV/FCF = 14.53x (Enterprise Value 5.53b / FCF TTM 380.4m)
FCF Yield = 6.88% (FCF TTM 380.4m / Enterprise Value 5.53b)
FCF Margin = 28.41% (FCF TTM 380.4m / Revenue TTM 1.34b)
Net Margin = 20.67% (Net Income TTM 276.7m / Revenue TTM 1.34b)
Gross Margin = 87.86% ((Revenue TTM 1.34b - Cost of Revenue TTM 162.6m) / Revenue TTM)
Gross Margin QoQ = 87.54% (prev 87.13%)
Tobins Q-Ratio = 1.73 (Enterprise Value 5.53b / Total Assets 3.19b)
Interest Expense / Debt = 10.13% (Interest Expense 4.12m / Debt 40.6m)
Taxrate = 25.03% (17.9m / 71.6m)
NOPAT = 209.1m (EBIT 278.9m * (1 - 25.03%))
Current Ratio = 3.17 (Total Current Assets 1.41b / Total Current Liabilities 443.5m)
Debt / Equity = 0.02 (Debt 40.6m / totalStockholderEquity, last quarter 2.59b)
Debt / EBITDA = -1.59 (Net Debt -603.2m / EBITDA 379.1m)
Debt / FCF = -1.59 (Net Debt -603.2m / FCF TTM 380.4m)
Total Stockholder Equity = 2.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.71% (Net Income 276.7m / Total Assets 3.19b)
RoE = 10.65% (Net Income TTM 276.7m / Total Stockholder Equity 2.60b)
RoCE = 10.57% (EBIT 278.9m / Capital Employed (Equity 2.60b + L.T.Debt 40.6m))
RoIC = 8.05% (NOPAT 209.1m / Invested Capital 2.60b)
WACC = 8.87% (E(6.13b)/V(6.17b) * Re(8.88%) + D(40.6m)/V(6.17b) * Rd(10.13%) * (1-Tc(0.25)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.47%
[DCF Debug] Terminal Value 75.80% ; FCFF base≈386.2m ; Y1≈407.0m ; Y5≈478.7m
Fair Price DCF = 127.4 (EV 7.11b - Net Debt -603.2m = Equity 7.72b / Shares 60.6m; r=8.87% [WACC]; 5y FCF grow 5.89% → 2.90% )
EPS Correlation: 19.21 | EPS CAGR: 3.85% | SUE: -0.61 | # QB: 0
Revenue Correlation: 24.78 | Revenue CAGR: 0.97% | SUE: 0.85 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.34 | Chg30d=-0.019 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-09-30): EPS=4.36 | Chg30d=+0.095 | Revisions Net=+1 | Growth EPS=+2.7% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.63 | Chg30d=+0.033 | Revisions Net=+1 | Growth EPS=+6.4% | Growth Revenue=+4.1%